Shinda Life Sciences: Dual-target weight loss drug maintained month-on-month growth trend in January, exceeding company expectations.

On February 9, the person in charge of related business at Xinda Biotech pointed out during an update conference call on the company's business progress that after the entry of the adaptability indications for Terlipressin and Semaglutide into medical insurance, there has been an overall adjustment in prices, which is within the company's expected range. In 2026, the adaptability indications for the company's Marcescens peptide may also participate in medical insurance negotiations. In response to these situations, the company implemented some strategies in January, offering discounts or promotions through different channels. "Overall, after a month, our sales are still good. Compared to December 2025, we are still maintaining a growth trend, actually exceeding our expectations."